MetaCap

Equillium (EQ) vs Organigram Global (OGI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Equillium (EQ) has outperformed Organigram Global (OGI) over the past year, gaining 10.4% versus a loss of 60.6%. Over five years, EQ leads with a -80.4% price change compared with -93.3% for OGI. Equillium is the larger company by market cap ($87.3 million vs $82.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EQ+10.42%OGI-60.61%
+248%+86%-75%
Nov 21, 20251 yearNov 20, 2026
EQ-79.81%OGI-92.71%
+13%-43%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EQ versus OGI key metrics
MetricEQOGI
Share price$1.06$0.583
Market cap$87.26M$82.27M
1-day change-5.36%-7.40%
YTD return-31.61%-65.30%
1-year return+10.42%-60.61%
5-year return-80.41%-93.25%
P/E ratio (TTM)—1.36
Forward P/E—27.76
EPS (TTM)$-0.12$0.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-22.40M—
52-week high$3.54$2.24
52-week low$0.81$0.583
Distance from 52-week high-70.06%-73.97%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+707.55%—
Average volume544.39K567.77K
Shares outstanding82.32M141.11M
Employees141,139
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EQ has outperformed OGI by 71.0 percentage points over the past year.

About Equillium

EQ stock →

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About Organigram Global

OGI stock →

Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees

EQ vs OGI FAQ

Which is bigger, Equillium or Organigram Global?

Equillium (EQ) is larger, with a market capitalization of $87.26M compared with $82.27M for Organigram Global (OGI).

Which stock has performed better over the past year, EQ or OGI?

EQ returned +10.42% over the past 12 months, compared with -60.61% for OGI (price return, excluding dividends). Past performance does not predict future results.

Are Equillium and Organigram Global in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons